The non-prostanoid IP receptor agonist, APD811 has potent antiproliferative and vasorelaxant properties in human pulmonary artery

Adams J¹, Shen L², Patel J², Norel X³, Clapp LH¹, Behan D¹

¹Arena Pharmaceuticals, Inc. San Diego, CA USA
²Institute of Cardiovascular Science, UCL, London UK
³INSERM U1148, CHU X. Bichat, Paris, France

Introduction: APD811 is a non-prostanoid IP receptor agonist with a long plasma half-life (~ 24hr) in clinical development by Arena for pulmonary arterial hypertension (PAH). The aim was to compare functional effects of APD811 in distal human pulmonary smooth muscle cells (PASMCs) and arteries (PAs) with other prostacyclin mimetics already licensed for PAH.

Methods: PASMCs from PAH patients were grown in 9% serum, treated with agonists±1 µM RO-1138452 (IP receptor antagonist) for 1 or 96hr and cAMP (ELISA) and cell proliferation (MTS) assessed. Distal PAs from control patients were mounted in a myograph and constricted with U46619 (thromboxane mimetic; 100nM). The concentration (EC₅₀) producing the half maximal response (E_max) was determined.

Results: Iloprost APD811, MRE-269 (selexipag metabolite) and treprostinil increased cAMP (EC₅₀ 17, 252, 340, 550 nM, respectively). E_max was lower (P<0.001) for all three agents compared with treprostinil. In proliferation assays, APD811 was 10 fold more potent (14 nM) than MRE-269 (145 nM) and E_max lower for both compared to treprostinil (57% versus 89%). RO-1138452 abolished agonist-induced cAMP generation and the antiproliferative effects of APD811 and MRE-269. In PAs, APD811 produced a significantly (P<0.001) greater relaxation (E_max 98%) compared to iloprost (E_max 84%), treprostinil (E_max 71%) or MRE-296 (E_max 59%) and was more potent (EC₅₀ 449nM versus 1579nM) than MRE-269.

Conclusions: APD811 and MRE-269 behave as selective, but partial IP receptor agonists, though APD811 produced superior effects to MRE-269 in all assays and had a favourable vasodilator profile compared with iloprost and treprostinil.